Cargando…

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metastasis. The terminal ACC lacks standard treatment guidelines and is always accompanied by poor prognosis. Here, we report a case of rare perianal ACC who received resec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shengnan, Li, Huiying, Lin, Yongjuan, Xie, Yu, Yin, Zhenyu, Ge, Weihong, Yu, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670344/
https://www.ncbi.nlm.nih.gov/pubmed/34321419
http://dx.doi.org/10.1097/CAD.0000000000001171
_version_ 1784614960678043648
author Zheng, Shengnan
Li, Huiying
Lin, Yongjuan
Xie, Yu
Yin, Zhenyu
Ge, Weihong
Yu, Tingting
author_facet Zheng, Shengnan
Li, Huiying
Lin, Yongjuan
Xie, Yu
Yin, Zhenyu
Ge, Weihong
Yu, Tingting
author_sort Zheng, Shengnan
collection PubMed
description Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metastasis. The terminal ACC lacks standard treatment guidelines and is always accompanied by poor prognosis. Here, we report a case of rare perianal ACC who received resection and palliative adjuvant radiation. Five years later, PET-computed tomography (CT) showed perianal recurrence and multiple pulmonary metastases. Combined chemotherapy with doxorubicin, carboplatin and cyclophosphamide was applied for two cycles but ineffective. Further next-generation sequencing analysis of perianal tissue demonstrated the v-myb avian myelobastosis viral oncogene homolog and nuclear factor I/B fusion gene and two novel BCL-6 corepressor (BCOR) mutations (p.F1106Tfs*5 and p.L1524Hfs*8). The therapy was switched to eribulin and anlotinib and has been performed for eight cycles. At recent follow-ups, MRI and CT examinations revealed the diminishing perianal and pulmonary lesions. This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC.
format Online
Article
Text
id pubmed-8670344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-86703442021-12-15 Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report Zheng, Shengnan Li, Huiying Lin, Yongjuan Xie, Yu Yin, Zhenyu Ge, Weihong Yu, Tingting Anticancer Drugs Clinical Reports Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metastasis. The terminal ACC lacks standard treatment guidelines and is always accompanied by poor prognosis. Here, we report a case of rare perianal ACC who received resection and palliative adjuvant radiation. Five years later, PET-computed tomography (CT) showed perianal recurrence and multiple pulmonary metastases. Combined chemotherapy with doxorubicin, carboplatin and cyclophosphamide was applied for two cycles but ineffective. Further next-generation sequencing analysis of perianal tissue demonstrated the v-myb avian myelobastosis viral oncogene homolog and nuclear factor I/B fusion gene and two novel BCL-6 corepressor (BCOR) mutations (p.F1106Tfs*5 and p.L1524Hfs*8). The therapy was switched to eribulin and anlotinib and has been performed for eight cycles. At recent follow-ups, MRI and CT examinations revealed the diminishing perianal and pulmonary lesions. This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC. Lippincott Williams & Wilkins 2021-07-30 2022-01 /pmc/articles/PMC8670344/ /pubmed/34321419 http://dx.doi.org/10.1097/CAD.0000000000001171 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Reports
Zheng, Shengnan
Li, Huiying
Lin, Yongjuan
Xie, Yu
Yin, Zhenyu
Ge, Weihong
Yu, Tingting
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title_full Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title_fullStr Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title_full_unstemmed Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title_short Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
title_sort treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670344/
https://www.ncbi.nlm.nih.gov/pubmed/34321419
http://dx.doi.org/10.1097/CAD.0000000000001171
work_keys_str_mv AT zhengshengnan treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT lihuiying treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT linyongjuan treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT xieyu treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT yinzhenyu treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT geweihong treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport
AT yutingting treatmentresponsetoeribulinandanlotinibinlungmetastasesfromrareperianaladenoidcysticcarcinomaacasereport